Late cervical and vaginal clear cell adenocarcinoma in women exposed in utero to diethylstilbestrol: Evaluation and screening

Tournaire, 2014, Diethylstilbestrol story, Therapie, 69, 101, 10.2515/therapie/2014012 Hoover, 2011, Adverse health outcomes in women exposed in utero to diethylstilbestrol, N Engl J Med, 365, 1304, 10.1056/NEJMoa1013961 Troisi, 2016, Prenatal diethylstilbestrol exposure and high-grade squamous cell neoplasia of the lower genital tract, Am J Obstet Gynecol, 215, 10.1016/j.ajog.2016.03.007 Hatch E., Karam A. Outcome and follow-up of diethylstilbestrol (DES) exposed individuals. UpToDate. Available at: https://www.uptodate.com/contents/outcome-and-follow-up-of-diethylstilbestrol-des-exposed-individuals ; 2022 [accessed on March 21, 2020 and March 30, 2023]. Hanselaar, 1997, Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks, Cancer, 79, 2229, 10.1002/(SICI)1097-0142(19970601)79:11<2229::AID-CNCR22>3.0.CO;2-X Herbst, 2015, Diethylstilbestrol (DES) pregnancy treatment : a promising widely used therapy with unintended adverse consequences, AMA J Ethics, 17, 865, 10.1001/journalofethics.2015.17.9.mhst1-1509 Huo, 2018, Follow-up of patients with clear-cell adenocarcinoma of the vagina and cervix, N Engl J Med, 378, 1746, 10.1056/NEJMc1800097 Lee, 2019, POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure, Gynecol Oncol Rep, 28, 15, 10.1016/j.gore.2019.01.012 White, 2022, Risk of clear-cell adenocarcinoma of the vagina and cervix among US women with potential exposure to diethylstilbestrol in utero, Cancer Causes Control, 33, 1121, 10.1007/s10552-022-01598-3 Wamakima, 2023, Postmenopausal vaginal and cervical cancer risk related to in utero diethylstilbestrol exposure, J Low Genit Tract Dis, 27, 35, 10.1097/LGT.0000000000000713 Agence Française de Sécurité SAnitaire des Produits de Santé (AFSSAPS) - Mise au point: Complications liées à l'exposition in utero au diethylstilbestrol (DES) (Distilbène®, Stilboestrol-Borne®) (2011). Avalaible at: https://ansm.sante.fr/uploads/2021/03/11/a2abb4db0658b1c97ade1be777f219ce.pdf [accessed on March 16, 2023]. Troisi, 2007, Cancer risk in women prenatally exposed to diethylstilbestrol, Intern J of Cancer, 121, 356, 10.1002/ijc.22631 Cancer Council Australia. Clinical Guidelines. Cervical cancer screening in DES-exposed women (2022). Available at: https://www.cancer.org.au/clinical-guidelines/cervical-cancer-screening/screening-in-des-exposed-women [accessed on March 16, 2023]. Hatch, 2001, Incidence of squamous neoplasia of the cervix and vagina in women exposed prenatally to diethylstilbestrol (United States), Cancer Causes Control, 12, 837, 10.1023/A:1012229112696 Verloop, 2017, Risk of cervical intra-epithelial neoplasia and invasive cancer of the cervix in DES daughters, Gynecol Oncol, 144, 305, 10.1016/j.ygyno.2016.11.048 Fontham, 2020, Cervical cancer screening for individuals at average risk: 2020 guideline update from the american cancer society, CA Cancer J Clin, 70, 321, 10.3322/caac.21628 Preventive Services Task Force, 2018, Screening for cervical cancer: US preventive services task force recommendation statement, JAMA, 320, 674, 10.1001/jama.2018.10897 American College of Obstetricians and Gynecologists (ACOG). Updated guidelines for management of cervical cancer screening abnormalities. 2020, Reaffirmed September 2022. Available at: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/10/updated-guidelines-for-management-of-cervical-cancer-screening-abnormalities [accessed on March 16, 2023]. Haute Autorité de Santé (HAS). Évaluation de la recherche des papillomavirus humains (HPV) en dépistage primaire des lésions précancéreuses et cancéreuses du col de l'utérus et de la place du double immuno-marquage p16/Ki67 (2019). Available at: https://www.has-sante.fr/jcms/c_2806160/fr/evaluation-de-la-recherche-des-papillomavirus-humains-hpv-en-depistage-primaire-des-lesions-precancereuses-et-cancereuses-du-col-de-l-uterus-et-de-la-place-du-double-immuno-marquage-p16/ki67 [accessed on March 16, 2023]. Institut National du Cancer (INCa). Dépistage du cancer du col de l'utérus – Le dépistage de 25 à 65 ans (2023). Available at: https://www.e-cancer.fr/Professionnels-de-sante/Depistage-et-detection-precoce/Depistage-du-cancer-du-col-de-l-uterus/Le-depistage-de-25-a-65-ans [accessed on March 16, 2023]. Levadou A, Tournaire M. Distilbène (DES) trois générations. Guide pratique pour les professionnels de santé et les familles DES. Association Réseau D.E.S. France ( 2021). Available at: https://www.des-france.org/wp-content/uploads/2021/12/Distilbene-Guide-Pratique-Resesau-DES-France-34-pages-Septembre-2021.pdf [accessed on March 16, 2023]. Tournaire, 2021, Screening for cancers of cervix and vagina for women exposed to diethylstibestrol (DES) in utero, J Gynecol Obstet Hum Reprod, 50, 10.1016/j.jogoh.2020.102042 American College of Obstetricians and Gynecologists (ACOG). Updated cervical cancer screening guidelines (2021). Available at : https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines [accessed on March 23, 2023]. National Cancer Institute (NCI). Diethylstilbestrol (DES) Exposure and Cancer (2021). Available at: https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/des-fact-sheet#what-should-des-daughters-do [accessed on March 23, 2023]. Institut National du Cancer (INCa). Etes-vous concernée par le dépistage du cancer du col de l'utérus ? (2023). Available at: https://www.e-cancer.fr/Comprendre-prevenir-depister/Se-faire-depister/Depistage-du-cancer-du-col-de-l-uterus/Etes-vous-concernee#toc-j-ai-t-expos-e-au-distilb-ne- [accessed on March 16, 2023]. Mergui, 2023, Nouvelle classification française des images colposcopiques [Revision of the French colposcopic terminology], Gynecol Obstet Fertil Senol., 5, 239